Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Research & Development (2016 - 2025)

Dexcom (DXCM) has disclosed Research & Development for 16 consecutive years, with $148.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 6.24% to $148.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $599.1 million, a 8.45% increase, with the full-year FY2025 number at $599.1 million, up 8.45% from a year prior.
  • Research & Development was $148.2 million for Q4 2025 at Dexcom, down from $157.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $157.5 million in Q3 2025 to a low of $109.4 million in Q1 2021.
  • A 5-year average of $132.9 million and a median of $135.6 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 61.58% in 2021, then dropped 22.36% in 2022.
  • Dexcom's Research & Development stood at $149.8 million in 2021, then dropped by 22.36% to $116.3 million in 2022, then grew by 17.02% to $136.1 million in 2023, then rose by 2.5% to $139.5 million in 2024, then rose by 6.24% to $148.2 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Research & Development are $148.2 million (Q4 2025), $157.5 million (Q3 2025), and $148.2 million (Q2 2025).